
Modeling Drug Combinations based on Molecular Structures and Biological Targets

Wengong Jin Regina Barzilay Tommi Jaakkola
CSAIL, Massachusetts Institute of Technology
{wengong,regina,tommi}@csail.mit.edu

Abstract

Drug combinations play an important role in therapeutics due to its better efficacy and reduced toxicity. Since validating drug combinations via direct screening is prohibitively expensive due to combinatorial explosion, recent approaches have applied machine learning to identify synergistic combinations for cancer. However, these approaches is not readily applicable to many diseases with limited combination data. Motivated by the fact that drug synergy is closely tied with biological targets, we propose a model that jointly learns drug-target interaction and drug synergy. The model, parametrized as a graph convolutional network, consists of two parts: a drug-target interaction and target-disease association module. These modules are trained together on drug combination screen as well as abundant drug-target interaction data. Our model is trained and evaluated on two SARS-CoV-2 drug combination screens and achieves 0.777 test AUC, which is 10% higher than the model trained without drug-target interaction.

1 Introduction

Combination therapies have shown to be more effective than single drugs in multiple diseases such as HIV and tuberculosis [26, 29]. Synergistic combinations can improve both potency and efficacy, either achieving stronger therapeutic effect and/or decreasing the dosage thereby reducing side-effects. In the times of the current public health crisis, finding a successful combination of approved molecules have an additional benefit over designing a de-novo molecule: time to clinical adoption. Approved drugs are typically commercially available and have well studied safety profiles. Taken in aggregate, these considerations motivate us to explore combination therapies for SARS-CoV-2 antivirals.

Since exploring the space of combinations via high-throughput screening is prohibitively expensive as it involves combinatorial search, in-silico screening based on machine learning is an appealing alternative. In fact, a number of such methods have been reported in the literature [23, 27]. These techniques have been shown effective when the model was provided with large amounts of training data capturing synergy of various combinations. Unfortunately, this requirement prevents us from utilizing these techniques for many diseases where such data is not available. Therefore, it is crucial to reduce data dependence to make combination algorithm applicable in multiple therapeutic contexts.

In this paper, we present a novel algorithm for finding combinations that achieves this goal. Our main hypothesis is that by explicitly modeling interaction between compounds and the biological targets, we can significantly decrease dependence on combination training data. The proposed model has two components. The first component models drug-target interactions (DTI) predicting which targets are inhibited by a compound. This component is trained on individual compounds since DTI information is readily available for multiple targets across multiple diseases. Our second component focuses on modeling target-disease association. Explicitly incorporating this information enables the model to capture the relation between targets that results in synergistic activity.

We further expand this basic architecture to refine our biological modeling. The first such expansion concerns target identification. Since our knowledge of disease relevant targets is often incomplete which may negatively impact model’s predictive power, we augment the target set with additional latent targets learned from single compound and combination data. Our second extension focuses on multi-disease training. Since screening data for combinations is typically sparse, we exploit additional combination data from related diseases for better generalization.

We develop our model using single agent and drug combinations of multiple diseases. The model incorporates known biological targets relevant to SARS-CoV-2 [9], as well as the corresponding drug-target activity data collected from ChEMBL [7]. Our model is evaluated on a SARS-CoV-2 combination screen from Bobrowski et al. [2] and achieves 0.777 AUC in terms of drug synergy prediction. Moreover, we demonstrate that incorporating known COVID targets and multi-disease training yields 50% relative increase in model accuracy. Finally, we show biological interpretation of the latent targets learned by the model.

2 Related Work

Existing approach on drug synergy prediction can be roughly divided into two categories:

- *Supervised learning*: In this approach, the model is trained on combination data generated from high-throughput screens. For example, Preuer et al. [23] have trained a deep neural network on a large-scale oncology screen [22] (23K training examples) to predict anti-cancer drug synergy. Xia et al. [27] and Sidorov et al. [25] have trained deep neural networks to predict anti-cancer drug synergy on a larger dataset compiled by NCI-ALMANAC [12], which contains around 300K training examples across 40 different cell lines.
- *Biological networks*: Another category of drug synergy models builds on biological networks, assuming that drugs with complementary mechanism of actions are more likely to be synergistic. In particular, Cheng et al. [3], Zhou et al. [30] proposed to model synergy using distance measures on drug-target interaction and protein-protein interaction networks.

The major challenge of supervised approaches is the lack of combination data. For many diseases such as SARS-CoV-2 and tuberculosis, the size of drug combination data is very limited (less than 200) [2, 29]. Deep learning methods are prone to over-fitting in this low-resource scenario. Moreover, the number of possible pair-wise combinations grows quadratically with the number of drugs. In fact, the current largest combination screen for cancer [12] only covers around 100 different drugs. This significantly limits the ability of trained models to generalize to new drugs outside of the training set. On the other hand, while network-driven methods have a wider coverage over the chemical space, they cannot make predictions on new compounds outside of the biological network (i.e., no edge between this compound and the targets) since the model is not parametric.

We propose a new method that combines the merit of both approaches while addressing their limitations. As drug interaction is often characterized by their biological targets, we train our model to predict both drug-target interaction and drug synergy. This enables us to make predictions on new compounds even if their drug-target interaction is unknown. This also addresses the data scarcity challenge since there are large amounts of drug-target interaction publicly available.

3 Method

In this section, we describe our model architecture for drug combinations. A drug combination is called synergistic if its antiviral effect is greater than the sum of the individual effects. Synergy arises from various types of drug interaction. For example, two drugs can be synergistic when they interact with different sets of biological targets or pathways. Indeed, most of the anti-HIV drug combinations, such as Dolutegravir and Lamivudine, are drugs with different mechanisms of actions (i.e., interacting with different biological targets). To account for this inductive bias, it is crucial to model the interaction between drugs and biological targets in our model architecture.

Motivated by these observations, we propose to decompose our model into two parts: a drug-target interaction (DTI) module ϕ and a target-disease association module f . The DTI module predicts the biological targets activated by a given compound. The target-disease association module decides the importance of a biological target to the disease. The vocabulary of biological targets are determined




Figure 1: Our model is composed of two modules: drug-target interaction and target-disease association module. The DTI vector characterizes the drug-target interaction profile of a given drug.

based on its relevance to the disease treatment given by expert knowledge. To introduce our method, we first describe how these two modules are used to predict antiviral activity of single compounds and then extend it to drug combinations.

3.1 Single Compound Model

Each drug is represented as a graph \mathcal{G} , whose nodes represent atoms and edges represent bonds. Each node/edge is labeled with its atom/bond type. To predict the antiviral effect of a single compound A , our model needs to accomplish two tasks: 1) it has to identify the interaction between A and a list of biological targets $\mathcal{V} = \{t_1, \dots, t_m\}$; 2) decide the relevance of each target t_i to the disease.

Drug-Target Interaction We parametrize the DTI module ϕ as a graph convolutional network (GCN) [5, 8]. The GCN translates a molecular graph \mathcal{G}_A into a continuous vector through directed message passing operations [28], which associate hidden vectors \mathbf{h}_v with each node v and updates these vectors by passing messages \mathbf{h}_{uv} over edges (u, v) . The output of ϕ is a vector \mathbf{z}_A representing the biological targets activated by drug A :

$$\mathbf{z}_A = \sigma(\text{MLP}(\sum_{v \in \mathcal{G}_A} \mathbf{h}_v)) \quad \{\mathbf{h}_v\} = \text{GCN}(\mathcal{G}_A) \quad (1)$$

where $\sigma(\cdot)$ is a sigmoid function and MLP is a two-layer feed-forward network. Each element $z_{A,k}$ represents the probability of drug A being active to target t_k . Each target t_k is associated with a drug-target interaction dataset $\mathcal{D}_k = \{(X_i, y_i)\}$, where $y_i = 1$ if a drug X_i is interacts with target t_k . We will train this module on the DTI dataset of all biological targets in our vocabulary.

Target-disease Association We parametrize the target-disease association module f as a simple linear layer (\mathbf{w}, \mathbf{b}) due to its interpretability. As shown in Figure 1, our model predicts its antiviral activity of a single drug A as:

$$p_A = f(\mathbf{z}_A) = \sigma(\mathbf{w}^\top \mathbf{z}_A + \mathbf{b}) \quad (2)$$

3.2 Drug Combination Model

Synergy are often quantified under Bliss independence assumption [1]: suppose the individual antiviral effect of drugs A, B are P_A, P_B . The expected effect of combination (A, B) is given as $E_{AB} = P_A + P_B - P_A P_B$. The drug pair (A, B) is synergistic if its observed effect $P_{AB} > E_{AB}$. Following this definition, we introduce a new Bliss layer to predict the synergistic effect of a drug combination (A, B) . Given two drugs and their predicted DTI vectors $\mathbf{z}_A, \mathbf{z}_B$, the Bliss layer computes the DTI vector \mathbf{z}_{AB} as

$$\mathbf{z}_{AB} = \mathbf{z}_A + \mathbf{z}_B - \mathbf{z}_A \odot \mathbf{z}_B \quad (3)$$

where \odot stands for element-wise multiplication. With this aggregation function, a drug combination will benefit most from *complementary* targets. If only one drug is active to target t_i (e.g., $z_{A,i} = 1, z_{B,i} = 0$), the combination (A, B) is still active to t_i ($z_{AB,i} = 1$). In other words, the set of active targets for (A, B) is the union of active targets of the two drugs.

As shown in Figure 2, for a drug combination (A, B) , our model predicts its antiviral activity as:

$$p_{AB} = f(\mathbf{z}_{AB}) = \sigma(\mathbf{w}^\top \mathbf{z}_{AB} + \mathbf{b}) \quad (4)$$

Following Bliss independence model, we predict the synergy score of a combination as $p_{AB} - e_{AB}$, where $e_{AB} = p_A + p_B - p_A p_B$. Intuitively, a combination is more likely to be synergistic if they have complementary targets with high target-disease association score.




Figure 2: Our model models drug interaction in terms of their biological targets. The antiviral effect of a combination is predicted on their DTI vector z_{AB} , which is computed from the predicted drug-target interaction vectors z_A, z_B of each individual drug.

3.3 Training Loss

Let ℓ be a cross-entropy loss. Our training loss $\mathcal{L} = \lambda_{\text{DTI}}\ell_{\text{DTI}} + \lambda_S\ell_S + \ell_C$ consists of three components:

- *DTI Loss*: The drug-target interaction loss ℓ_{DTI} enforces the predicted DTI vector z_A to be biologically accurate. The corresponding training data is the union of DTI datasets $\mathcal{D}_{\text{DTI}} = \bigcup_k \mathcal{D}_k$. For each drug and its DTI label $(X_i, y_i) \in \mathcal{D}_{\text{DTI}}$, the DTI module ϕ is trained to minimize:

$$\ell_{\text{DTI}} = \sum_k \sum_{(X_i, y_i) \in \mathcal{D}_k} \ell(z_{X_i, k}, y_i) \quad (5)$$

- *Single Compound Loss*: Our second training data $\mathcal{D}_S = \{(X_1, y_1), \dots, (X_n, y_n)\}$ contains molecules and their labeled antiviral activity (active/inactive). Both modules ϕ, f are trained to minimize

$$\ell_S = \sum_{(X_i, y_i) \in \mathcal{D}_S} \ell(f(\phi(X_i)), y_i) \quad (6)$$

- *Combination Loss*: The third training data $\mathcal{D}_C = \{(A_i, B_i, y_i)\}$ contains drug combinations and their labeled synergy. $y_i = 1$ means (A_i, B_i) is synergistic and $y_i = 0$ additive or antagonistic. We train both modules ϕ, f to minimize

$$\ell_C = \sum_{(A_i, B_i, y_i) \in \mathcal{D}_C} \ell(p_{A_i B_i} - e_{A_i B_i}, y_i) \quad (7)$$

3.4 Extensions

We further introduce two extensions to the basic architecture described above that lead to notable performance improvement in practice:

Latent Targets In order to learn synergy, it is important to incorporate all the relevant biological targets into our model. However, this is challenging for two reasons: First, many biological targets do not have drug-target interaction data and thus cannot be incorporated in our model. Second, the current biological understanding of a disease may be incomplete. For instance, Riva et al. [24] reported around 50 new biological targets that contributes to anti-SARS-CoV-2 activity, but they are not reported in the previous work by Gordon et al. [9].

To this end, we propose to create additional *latent targets* that can be learned indirectly from single compound and combination data. Specifically, we allow the dimension of z_A to be greater than the total number of considered targets in \mathcal{V} . The first m entries in z_A corresponds to the real biological targets and the other entries are latent targets. As we will show in the experiments, it is possible for us to identify new biological targets related to given diseases.

Multi-Disease Training Another challenge is the scarcity of drug combination data. To our best knowledge, there are only around 180 drug combinations with labeled synergy against SARS-CoV-2. To address the low-resource challenge, we utilize drug synergy data from other viral diseases such

as HIV. In particular, we augment our model with additional HIV biological targets as well as HIV single-drug and drug combination data. The HIV related datasets will be elaborated in Section 4.

The DTI module ϕ now outputs a DTI vector z_A^d for each disease d . ϕ is shared across two diseases and trained to learn drug-target interaction for all diseases. Since each disease operates on different targets, we create a target-disease association module f^D for each disease. Let $\ell_{\text{DTI}}^d, \ell_S^d, \ell_C^d$ be the losses for each disease $d \in \{\text{SARS-CoV-2, HIV}\}$ computed from its own dataset. Our multi-disease training loss becomes

$$\mathcal{L}_{\text{multi}} = \sum_d \lambda_1 \ell_{\text{DTI}}^d + \lambda_2 \ell_S^d + \ell_C^d \quad (8)$$

4 Experiments

SARS-CoV-2 Data For SARS-CoV-2 infection, we consider three types of biological targets in our target vocabulary $\mathcal{V} = \{t_1, \dots, t_m\}$:

- *Viral proteases*: Replication of SARS-CoV-2 virus requires the processing of two polyproteins by two virally encoded proteases: chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro). Inhibitors that block either protease could inhibit viral replication. We have compiled 3CLpro enzymatic activity [16] and PLpro inhibition [4] data made public by NCATS and ReframedB.
- *Viral entry proteins*: SARS-CoV-2 cell entry depends on angiotensin converting enzyme 2 (ACE2) [11]. Inhibiting ACE2 enzyme or the interaction between SARS-CoV-2 and ACE2 could block viral entry. To this end, we utilize ACE2 enzymatic activity [17] and Spike-ACE2 protein-protein interaction [20] from NCATS.
- *Host proteins*: Gordon et al. [9] identified 335 human proteins physically associated with SARS-CoV-2 viral proteins. Inhibitors for these proteins may also hinder viral replication. Among these proteins, we selected 31 proteins that have sufficient amount of drug-target interaction data in the ChEMBL database (i.e., both positive and negative interactions).

The above drug-target interaction data contains around 20K compounds in total. Our training data for SARS-CoV-2 utilizes another two assays:

- *Single-agent Activity*: We use the NCATS CPE assay in VeroE6 cells [18], which contains around 10K compounds and 320 hits with $\text{EC}_{50} \leq 10\mu\text{M}$.
- *Drug Combination*: NCATS performed two combination assays in VeroE6 cells, which contain 160 two-drug combinations [2, 19]. Riva et al. [24] also analyzed synergy between Remdesivir and 20 active compounds identified from their high-throughput screen.

HIV Data The training data for HIV comes from the following assays:

- *Drug-target Interaction*: Existing anti-HIV drugs mainly target viral proteins (HIV-1 protease, integrase and reverse transcriptase) or host proteins involved in viral entry (CCR5, CXCR4 and CD4). We compiled DTI data for these six targets from ChEMBL.
- *Single-agent Activity*: NCI conducted an anti-HIV assay [21] with 35K compounds, among which 309 compounds are active ($\text{EC}_{50} \leq 1\mu\text{M}$).
- *Drug Combination*: Tan et al. [26] conducted high-throughput screen for HIV drug combinations. The dataset contains 114 two-drug combinations.

Evaluation Protocol Since our goal is to predict synergy against SARS-CoV-2, our validation and test set only consist of SARS-CoV-2 combinations. All the drug-target interaction, single-drug activity and HIV data are used for training only. Our validation set contains 20 combinations from Riva et al. [24] and test set contains 72 combinations from Bobrowski et al. [2]. The training set contains 90 SARS-CoV-2 combinations from [19], where we remove combinations that appear in both the training and test set.

Hyperparameters For DTI module ϕ , we adopt default hyperparameters from Yang et al. [28], with hidden dimension 300 and three message passing iterations. We set the dimension of DTI vector $|z| = 100$, with 42 real biological targets (SARS-CoV-2 and HIV) and 58 latent targets, so that the number of real and latent targets are roughly equal. We set $\lambda_1 = 10, \lambda_2 = 0.1$ for our final model.




Figure 3: *Left*: Results on SARS-CoV-2 combination test set. Our model (+all) outperforms all other baselines. *Right*: Interpretation of latent targets to new biological targets identified by Riva et al. [24]. The blue circles represent latent targets learned by our best model and the red circles represent new biological targets. We draw an edge between a latent target and a biological target if their matching AUROC is higher than 0.7.

4.1 Results

To show the effectiveness of different components, we compare with the following baselines:

- A GCN trained only on SARS-CoV-2 single-agent and combination data ($\lambda_{\text{DTI}} = 0, |\mathbf{z}| = 100$).
- +DTI: A GCN trained only on SARS-CoV-2 single-agent, combination as well as drug-target interaction data ($\lambda_{\text{DTI}} = 10, |\mathbf{z}| = 100$).
- +MultiD: A GCN trained on both SARS-CoV-2 and HIV data (single-agent + combination), but without drug-target interaction data ($\lambda_{\text{DTI}} = 0, |\mathbf{z}| = 100$).
- +All,-latent: A GCN trained on both SARS-CoV-2 and HIV data (single-agent + combination + drug-target interaction), but the latent targets are removed ($\lambda_{\text{DTI}} = 10, |\mathbf{z}| = 42$).
- +All: A GCN trained on both SARS-CoV-2 and HIV data (single-agent + combination + drug-target interaction), but the latent targets are removed ($\lambda_{\text{DTI}} = 10, |\mathbf{z}| = 100$).

Our results are shown in Figure 3. As expected, the GCN baseline performs poorly, with 0.537 ± 0.075 AUC. Adding drug-target interaction data (+DTI) improves the AUC to 0.658 ± 0.079 . Adding HIV data (+MultiD) improves the AUC to 0.706 ± 0.088 . Our final model, trained with both HIV and drug-target interaction (+All), achieves the best AUC of 0.777 ± 0.066 . This validates the advantage of adding drug-target interaction data and multi-disease training. Note that if we remove the latent targets (+All,-latent), the performance decreases to 0.718 ± 0.021 . This also shows the importance of using latent targets to complement missing biological information.

4.2 Latent Target Interpretation

While the latent targets are trained to represent biological targets, we found that they are predictive of certain SARS-CoV-2 biological targets that are not provided during training. Therefore, we propose to interpret their biological meaning by the following procedure:

1. Suppose we have a list of real SARS-CoV-2 targets $\mathcal{C} = \{c_1, \dots, c_n\}$ that are not provided to the model during training (i.e., $\mathcal{V} \cap \mathcal{C} = \emptyset$). Let \mathcal{D}_{c_j} be the drug-target interaction dataset for c_j .
2. Compute DTI vectors $\mathbf{z}_{X_1}, \dots, \mathbf{z}_{X_n}$ for each compound $X_i \in \mathcal{D}_{c_j}$. For each latent target k , compute the AUROC between DTI labels y_1, \dots, y_n and predicted DTI scores $\mathbf{z}_{X_1,k}, \dots, \mathbf{z}_{X_n,k}$.
3. Match latent target k to target c_j if the AUROC is higher than threshold $\tau = 0.7$.

The target set \mathcal{C} contains 34 biological targets reported in Riva et al. [24] that are correlated with SARS-CoV-2 antiviral activity and have drug-target interaction data in the ChEMBL database. These targets are not provided to the model during training. As shown in Figure 3, among the 58 latent targets, 27 of them are matched to the antiviral targets in Riva et al. [24] using the above procedure. This shows that our model is capable of capturing additional SARS-CoV-2 targets through single-agent and combination data.

5 Conclusion

In this paper, we present a new algorithm for predicting SARS-CoV-2 drug synergy. The model consists of two components: a drug-target interaction module and target-disease association module. Our method requires much less combination data since we explicitly model the drug-target interaction in our model architecture. The proposed method is general and applicable to many other diseases.

References

- [1] Chester I Bliss. The toxicity of poisons applied jointly 1. *Annals of applied biology*, 26(3): 585–615, 1939.
- [2] Tesia Bobrowski, Lu Chen, Rich T Eastman, Zina Itkin, Paul Shinn, Catherine Chen, Hui Guo, Wei Zheng, Sam Michael, Anton Simeonov, et al. Discovery of synergistic and antagonistic drug combinations against sars-cov-2 in vitro. *BioRxiv*, 2020.
- [3] Feixiong Cheng, István A Kovács, and Albert-László Barabási. Network-based prediction of drug combinations. *Nature communications*, 10(1):1–11, 2019.
- [4] Meredith Davis-Gardner. Sars-cov-2 plpro inhibitor assay. 2020. <https://reframedb.org/assays/A00461>.
- [5] David K Duvenaud, Dougal Maclaurin, Jorge Iparraguirre, Rafael Bombarell, Timothy Hirzel, Alán Aspuru-Guzik, and Ryan P Adams. Convolutional networks on graphs for learning molecular fingerprints. In *Advances in neural information processing systems*, pages 2224–2232, 2015.
- [6] Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, et al. Identification of inhibitors of sars-cov-2 in-vitro cellular toxicity in human (caco-2) cells using a large scale drug repurposing collection. 2020.
- [7] Anna Gaulton, Anne Hersey, Michał Nowotka, A Patricia Bento, Jon Chambers, David Mendez, Prudence Mutowo, Francis Atkinson, Louisa J Bellis, Elena Cibrián-Uhalte, et al. The chembl database in 2017. *Nucleic acids research*, 45(D1):D945–D954, 2017.
- [8] Justin Gilmer, Samuel S Schoenholz, Patrick F Riley, Oriol Vinyals, and George E Dahl. Neural message passing for quantum chemistry. *arXiv preprint arXiv:1704.01212*, 2017.
- [9] David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O’Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, et al. A sars-cov-2 protein interaction map reveals targets for drug repurposing. *Nature*, pages 1–13, 2020.
- [10] Deisy Morselli Gysi, Ítalo Do Valle, Marinka Zitnik, Asher Ameli, Xiao Gan, Onur Varol, Helia Sanchez, Rebecca Marlene Baron, Dina Ghiassian, Joseph Loscalzo, et al. Network medicine framework for identifying drug repurposing opportunities for covid-19. *arXiv preprint arXiv:2004.07229*, 2020.
- [11] Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche, et al. Sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. *Cell*, 181(2):271–280, 2020.
- [12] Susan L Holbeck, Richard Camalier, James A Crowell, Jeevan Prasaad Govindharajulu, Melinda Hollingshead, Lawrence W Anderson, Eric Polley, Larry Rubinstein, Apurva Srivastava, Deborah Wilsker, et al. The national cancer institute almanac: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. *Cancer research*, 77(13):3564–3576, 2017.
- [13] Wengong Jin, Regina Barzilay, and Tommi Jaakkola. Adaptive invariance for molecule property prediction. *arXiv preprint arXiv:2005.03004*, 2020.

- [14] Wengong Jin, Regina Barzilay, and Tommi Jaakkola. Domain extrapolation via regret minimization. *arXiv preprint arXiv:2006.03908*, 2020.
- [15] S Loewe. Die quantitativen probleme der pharmakologie. *Ergebnisse der Physiologie*, 27(1): 47–187, 1928.
- [16] National Center for Advancing Translational Sciences (NCATS). Sars-cov-2 3cl protease enzymatic activity. 2020. <https://opendata.ncats.nih.gov/covid19/assay?aid=9>.
- [17] National Center for Advancing Translational Sciences (NCATS). Ace2 enzymatic activity. 2020. <https://opendata.ncats.nih.gov/covid19/assay?aid=6>.
- [18] National Center for Advancing Translational Sciences (NCATS). Sars-cov-2 cytopathic effect (cpe) screening. 2020. <https://opendata.ncats.nih.gov/covid19/assay?aid=14>.
- [19] National Center for Advancing Translational Sciences (NCATS). In vitro sars-cov-2 evaluation of drug combinations for exploring chemical biology and potential therapeutic use. 2020. <https://tripod.nih.gov/matrix-client/?project=2983>.
- [20] National Center for Advancing Translational Sciences (NCATS). Sars-cov-2 spike-ace2 protein-protein interaction (alphalisa). 2020. <https://opendata.ncats.nih.gov/covid19/assay?aid=1>.
- [21] National Cancer Institute (NCI). Aids antiviral screen data. 2004. <https://wiki.nci.nih.gov/display/NCIDTPdata/AIDS+Antiviral+Screen+Data>.
- [22] Jennifer O’Neil, Yair Benita, Igor Feldman, Melissa Chenard, Brian Roberts, Yaping Liu, Jing Li, Astrid Kral, Serguei Lejnine, Andrey Loboda, et al. An unbiased oncology compound screen to identify novel combination strategies. *Molecular cancer therapeutics*, 15(6):1155–1162, 2016.
- [23] Kristina Preuer, Richard PI Lewis, Sepp Hochreiter, Andreas Bender, Krishna C Bulusu, and Günter Klambauer. Deepsynergy: predicting anti-cancer drug synergy with deep learning. *Bioinformatics*, 34(9):1538–1546, 2018.
- [24] Laura Riva, Shuofeng Yuan, Xin Yin, Laura Martin-Sancho, Naoko Matsunaga, Lars Pache, Sebastian Burgstaller-Muehlbacher, Paul D De Jesus, Peter Teriete, Mitchell V Hull, et al. Discovery of sars-cov-2 antiviral drugs through large-scale compound repurposing. *Nature*, pages 1–11, 2020.
- [25] Pavel Sidorov, Stefan Naulaerts, Jérémy Ariey-Bonnet, Eddy Pasquier, and Pedro Ballester. Predicting synergism of cancer drug combinations using nci-almanac data. *Frontiers in chemistry*, 7:509, 2019.
- [26] Xu Tan, Long Hu, Lovelace J Luquette, Geng Gao, Yifang Liu, Hongjing Qu, Ruibin Xi, Zhi John Lu, Peter J Park, and Stephen J Elledge. Systematic identification of synergistic drug pairs targeting hiv. *Nature biotechnology*, 30(11):1125–1130, 2012.
- [27] Fangfang Xia, Maulik Shukla, Thomas Brettin, Cristina Garcia-Cardona, Judith Cohn, Jonathan E Allen, Sergei Maslov, Susan L Holbeck, James H Doroshov, Yvonne A Evrard, et al. Predicting tumor cell line response to drug pairs with deep learning. *BMC bioinformatics*, 19(18):71–79, 2018.
- [28] Kevin Yang, Kyle Swanson, Wengong Jin, Connor Coley, Philipp Eiden, Hua Gao, Angel Guzman-Perez, Timothy Hopper, Brian Kelley, Miriam Mathea, et al. Analyzing learned molecular representations for property prediction. *Journal of chemical information and modeling*, 59(8):3370–3388, 2019.
- [29] Kaan Yilancioglu and Murat Cokol. Design of high-order antibiotic combinations against m. tuberculosis by ranking and exclusion. *Scientific reports*, 9(1):1–11, 2019.
- [30] Yadi Zhou, Yuan Hou, Jiayu Shen, Yin Huang, William Martin, and Feixiong Cheng. Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2. *Cell discovery*, 6(1):1–18, 2020.